Novartis Opens Door to Broad Dealmaking in RNAi
This article was originally published in Start Up
Executive Summary
Novartis has seemingly changed the RNAi therapeutics game with its potential blockbuster deal with Alnylam, suggesting that getting to the bottom of RNAi's therapeutic possibilities requires significant assets and staying power.